To see how niosomal formulation affects the treatment of breast cancer cells and the synergistic effect of TMX and Cur, expression of three different genes (bax, bcl2, and p53) was measured within the MCF-7 breast cancer cell line. This evidence concerns the gene BCL2 and breast carcinoma.